ClinicalTrials.gg
Enrolling by invitationNCT06642662Updated Apr 2, 2026

Precision Medicine in the CICU: Identifying Proteomic Biomarkers

An observational study in Congenital Heart Disease, sponsored by Boston Children's Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 2 Days to 5 Years. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Boston Children's Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
2 Days to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Heart Defects, Congenital by Boston Children's Hospital — 9 open to participants now, 10 under way, none of them phase 3. Heart Defects, Congenital · Boston Children's Hospital.

Planned enrollment
11th of 19
60 · median 64
Started
2025
with 1 other
Observational
19 of 37
8 open now
Registered
33rd of 37
by date

Among the 37 studies in Heart Defects, Congenital by Boston Children's Hospital, this one is the 11th largest by planned enrollment of the 19 observational ones that give a count, is one of 2 that started in 2025, is one of 19 observational ones, and was the 33rd registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

9 of the 37 studies in Heart Defects, Congenital by Boston Children's Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 2 Days to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Heart Defects, Congenital by Boston Children's Hospital, or all of them as a file.
02

Study summary

Congenital Heart disease (CHD) is a leading cause of childhood death. Substantial morbidity and mortality relates to the postoperative course. For example, only 70% of neonates survive to hospital discharge after their first complex surgery for single ventricle heart disease. Adverse systemic inflammatory responses are highly exaggerated in some children postoperatively. This inflammation is pathological, results in leaky blood vessels and fluid overload, toxin release as well as cell damage contributing to lung, heart and kidney injury. Reasons why some children develop this amplified systemic inflammatory response after heart surgery while others do not are poorly understood. Mechanisms for how cardiopulmonary bypass and surgery drive this inflammation are also inadequately characterized. Currently, there are no existing methods to predict patients at high-risk for acute adverse postoperative complications, let alone adjust our management to mitigate these effects. Instead, our postoperative care approach is a one-size fits all, reactive process 'after' patients become inflamed or adverse events occur.

Proteins in a patient's blood participate in and reflect acute inflammatory responses. In other pediatric conditions, protein biomarkers have been shown to both predict and monitor inflammation and adverse outcomes, and importantly predict responsiveness to anti-inflammatory drug therapies. This is the premise of precision medicine. Personalizing treatment to each individual patient.

New technologies now allow the levels of tens of thousands of proteins to be measured from a few drops of blood. In this proposal the investigators will identify predictors of adverse events after heart surgery by quantifying protein levels and their changes after surgery. It is now possible to detect those proteins with the greatest variability in the postoperative course over time, and between patients, as well as those that are associated with adverse outcomes. The most informative proteins will yield insights into the causes of the inflammatory response. The investigators anticipate identifying protein plasma biomarkers in pathways associated with inflammation, metabolism, blood vessel function and the immune system as these may be key mechanisms involved. Advanced understanding of these mechanisms is critical to deriving targeted therapies to prevent or mitigate inflammatory responses.

The investigators will also collect patient clinical data, such as age, cardiac anatomy, and duration of surgery. By combining this clinical information with blood protein profiles, the investigators will be able to develop a model predicting patients at highest risk for adverse postoperative events using machine learning approaches. The overarching goal of this research integrating clinical and bench research is ultimately to translate precision medicine approaches to the Cardiac ICU. Guiding personalized care of high-risk patients by enabling clinicians to anticipate outcomes and tailor decision-making at the bedside will undoubtably improve outcomes in CHD.

Read the detailed description

Acute inflammation following cardiopulmonary bypass (CPB) contributes to morbidity and mortality; however, mechanisms eliciting these responses and biomarkers predicting at-risk patients remain unidentified. Proteins are disease-associated circulating factors in patients' blood that both participate in and reflect inflammation. Existing data suggests proteomic biomarkers hold promise for predicting and monitoring inflammation and adverse outcomes; however, further research is needed to validate biomarkers in pediatric cardiac disease, elucidate underlying mechanisms of CPB-induced inflammation, and translate them to clinical practice.

Specific Aims: Our overarching goal is to integrate quantitative biomarkers with clinical medicine to enhance care of patients with congenital heart disease (CHD) by personalizing their treatment. The investigators propose a first step towards a precision medicine paradigm for children with CHD, many of whom experience inflammation post-CPB. The investigators hypothesize that proteomic profiling will detect biomarkers that identify patients at highest risk for exaggerated systemic inflammatory responses to CPB. The investigators will conduct a pilot feasibility study integrating unbiased proteome-wide discovery approaches, to offer a deep and unbiased view of the proteomic landscape underlying pathological processes post-CPB (Fig. 1).

AIM 1: To prospectively enroll patients with CHD undergoing CPB in a study of quantitative proteomic profiles.

Hypothesis: Conducting an observational study utilizing unbiased proteome-wide discovery approaches in children in the cardiac intensive care unit (CICU) undergoing CPB is feasible. The investigators will identify 80 children in 3 diagnosis cohorts. Those undergoing stage 1 palliation (S1P) for hypoplastic left heart syndrome (HLHS), or biventricular (BiV) repair both have elevated risk of exaggerated inflammatory responses with postoperative courses characterized by fluid overload, prolonged mechanical ventilation, fevers, and capillary leak, and those with D-transposition of the great arteries (DTGA) post arterial switch operation (ASO) have lower risk. The investigators will collect demographic and clinical data and obtain blood samples at four time points: pre-CPB, immediately post-CPB, 12 hrs post-CPB, and 24 hrs post-CPB. Plasma will be analyzed on the SomaScan v5.0 platform, which measures 10,778 proteins from a 55 µL plasma sample.

AIM 2: To enhance understanding of inflammatory responses in children undergoing CPB by characterizing proteomic changes. Hypothesis: Temporal intra-patient proteomic responses to CPB and their relationships with outcomes will be characterized by the SomaScan platform. The investigators will describe dynamic intra-patient temporal variability in protein levels from pre- to post-CPB. Next, the investigators will identify proteins that demonstrate the greatest variability between patients overall, across timepoints, and between patients, stratified by outcome. To discriminate candidate biomarkers of postoperative inflammation and adverse outcomes, the investigators will study three clinical endpoints: time to successful extubation, extent of fluid overload in the 72 hours post-CPB, and a composite binary adverse outcome. The biomarker search will be unbiased and broad, with control for false discovery. Predictive proteins will be validated by targeted multiplex immunoassay and pathways described using systems biology approaches.

AIM 3: To develop a machine learning classifier predicting patient outcomes based on proteomic profiles and clinical variables. Hypothesis: Adverse outcomes following CPB will be predicted by a combination of clinical and proteomic biomarkers. The investigators will use supervised machine learning classifier approaches to discriminate and define the combination of proteomic and peri-operative clinical features (e.g. age, cardiac morphology/surgery, CPB, and circulatory arrest times) that accurately differentiate individuals at high risk of acute post-operative adverse events.

03

Conditions studied

  • Congenital Heart Disease

Keywords

  • proteomic
  • pediatric cardiac surgery
  • cardiopulmonary bypass
04

Who can participate

Ages eligible
2 Days to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Prospective patients undergoing S1P for HLHS, BiV repair, or ASO will be identified. Inclusion: elective BiV repair in patients aged >1 and \<5 years or standard risk S1P/ASO. Exclusion: preoperative ventilation or vasoactive support. With primary treating team approval, the investigators will approach parents of eligible patients to discuss study participation with written informed consent obtained if they agree to enroll.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • consent from parents
  • cardiac surgical criteria and age criteria; elective BiV repair in patients aged >1 and \<5 years or standard risk S1P/ASO

Exclusion criteria

Exclusion Criteria:

  • preoperative ventilation or vasoactive support or ECMO
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
3 Weeks
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • DTGA ASO

    D-transposition of the great arteries (DTGA) post arterial switch operation (ASO)

    Diagnostic Test: Somascan 5.0

  • S1P

    Neonates undergoing stage 1 palliation (S1P) for hypoplastic left heart syndrome (HLHS)

    Diagnostic Test: Somascan 5.0

  • BiV

    Prior single ventricle palliation now undergoing biventricular (BiV) repair

    Diagnostic Test: Somascan 5.0

Interventions

  • Diagnostic testSomascan 5.0

    This observational study will test patient plasma using the SomaScan platform, a highly multiplexed proteomic tool that uses SOMAmers (Slow Off-rate Modified Aptamers) to bind with high specificity and affinity to preselected proteins to quantify levels. SomaScan v5.0 quantifies 10,778 clinically relevant human proteins, with several thousand proteins linked to inflammation and immune system functions, across a wide range of concentrations (\>10 logs) with high sensitivity (\<1 pg/mL) and reproducibility (median coefficient of variation \< 5%). Individual protein concentrations are transformed into a corresponding SOMAmer concentration and quantified using a DNA microarray read-out.

06

What researchers measure

Primary outcomes

  1. Time in hours to successful extubation

    Time to successful extubation in hours

    Time frame: through ICU admission, average 1 week

Secondary outcomes

  1. Extent of fluid overload

    Extent of cumulative fluid overload in the 72 hours post-bypass represented as a proportion of fluid balance by body weight

    Time frame: 3 days

  2. Composite adverse outcome

    The proportion meeting a composite binary adverse outcome; ie the proportion with a cardiac arrest, mechanical support, organ failure, or death within 7 days of surgery.

    Time frame: 7 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — The investigators may share deidentified high dimensional proteomics data with the broader scientific and clinical community.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 178 non-industry observational studies under Heart Defects, Congenital, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 83. This study's planned 19 months is below that.

Counting every sponsor, half of 185 studies reached it within 44 months; a quarter within 17 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartActual
Apr 15, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Apr 15, 2027
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06642662
Responsible party
Katie Moynihan (Director of Palliative Care Services, Division of Cardiovascular Critical Care, Department of Cardiology, Boston Children's Hospital) — Principal investigator
First posted
Oct 15, 2024
Start date
Apr 15, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Apr 15, 2027 (estimated)
Last update
Apr 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion